In a development that bridges artificial intelligence, drug discovery, and the science of aging, Insilico Medicine has unveiled early data suggesting that an AI-designed lung drug may also reverse biological markers of aging. The company, known for using generative AI to identify therapeutic targets and design novel molecules, presented findings from a post-hoc analysis of its Phase IIa trial of rentosertib, an investigational candidate for idiopathic pulmonary fibrosis (IPF). The analysis showed that treatment was associated with a reduction in biological age, as measured by six independent proteomic aging clocks.

A Drug Born From AI, Tested for Aging

Rentosertib, also known as INS018_055, is an oral small molecule inhibitor of TNIK (TRAF2 and NCK-interacting kinase), a target that Insilico's AI platform flagged as central to the fibrotic pathway. The drug was originally designed to treat IPF, a chronic and progressive lung disease that causes scarring of the lungs and has few effective treatments. In May 2024, Insilico reported positive topline results from the Phase IIa trial, demonstrating a favorable safety profile and signs of efficacy in lung function measures.

The new analysis, reported by multiple outlets including Bloomberg, The New York Times, and MarketWatch, goes a step further by examining whether rentosertib could influence the aging process itself. Researchers used blood samples from trial participants and applied six previously validated proteomic aging clocks—algorithms that estimate biological age from protein levels in the blood. The results indicated that after treatment, patients' biological age appeared to decrease relative to their chronological age, suggesting a potential senolytic or anti-aging effect.

CEO and Co-CEO Weigh In

Insilico's founder and CEO, Alex Zhavoronkov, has long championed the idea that AI can accelerate the development of longevity therapeutics. Speaking with Bloomberg, he discussed the broader implications of the findings. According to the company's co-CEO, there are 'big hopes' that the same drug, initially developed for fibrosis, could also be repurposed as an anti-aging intervention. The sentiment was captured in a headline from MSN, which quoted Insilico's co-CEO expressing cautious optimism about the dual potential.

'We have big hopes that this fibrosis drug can reverse aging too.' — Insilico Medicine executive

However, the company stopped short of claiming that rentosertib is a proven anti-aging therapy. The findings are preliminary, based on a small number of patients, and the analysis was retrospective. Researchers not involved in the study have urged caution, noting that biological age clocks are surrogate endpoints, not proof of longevity in humans.

How the Coverage Frames the Story

The announcement generated varied framing across news outlets. Bloomberg Markets focused on Zhavoronkov's personal commentary and the investment implications, highlighting how AI-driven biotech companies are increasingly turning to longevity indications. The New York Times, in its early coverage, emphasized that the data is 'early' and that many such findings fail to replicate in larger trials. MarketWatch described the drug as showing 'anti-aging potential' while noting that the study was industry-sponsored and not yet peer-reviewed. News-Medical.net delivered a more breathless summary, proclaiming that the drug candidate 'reverses biological age'—a claim that drew pushback from some geroscience experts who argue that reversing a biomarker is not equivalent to reversing aging itself.

  • Bloomberg Markets: Focused on CEO Alex Zhavoronkov's commentary and the business strategy of applying AI to longevity.
  • The New York Times: Stressed caution, calling the data 'early' and pointing to past disappointments in the anti-aging drug field.
  • MarketWatch: Balanced optimism with a reminder that the research is company-sponsored and unpeer-reviewed.
  • MSN: Highlighted the co-CEO's personal hopes, suggesting that the company sees a future beyond fibrosis.
  • News-Medical.net: Took a promotional tone, emphasizing the drug's 'reversal' of biological age.
  • Yahoo Finance: Noted the drug's name, rentosertib, and its assessment by six proteomic aging clocks, indicating a rigorous analytical approach.

What Are Proteomic Aging Clocks?

Biological age, unlike chronological age, is a measure of how well a person's body is functioning at the molecular level. Proteomic clocks use machine learning to predict biological age from the relative abundance of proteins in the blood. Six different clocks were employed in this analysis, each developed independently and capturing different aspects of aging. The fact that all six showed a consistent signal strengthens the case, though it does not confirm clinical benefit. 'This is an encouraging signal, but we need to see whether these changes translate into actual healthspan improvements,' said an expert in aging research who was not part of the study.

Implications for AI-Driven Drug Discovery

For the broader field of AI-driven drug discovery, the findings serve as a proof-of-concept. Insilico's approach—training deep learning models on vast biomedical datasets to identify targets and then generating novel molecules—has been validated by the successful advance of rentosertib to mid-stage clinical trials. If the same platform can identify compounds that affect aging pathways, the potential market is enormous. The global longevity and anti-aging market is projected to exceed $100 billion by 2030, according to industry analysts. But the road from biomarker improvements to regulatory approval for an anti-aging indication is steep. The Food and Drug Administration does not currently accept biological age as a valid endpoint for drug approval.

What's Next

Insilico says it plans to conduct larger, prospective trials that include aging-related endpoints such as frailty, quality of life, and perhaps even mortality. The company is also exploring other indications for rentosertib, including systemic sclerosis and chronic liver disease. Zhavoronkov has stated publicly that he envisions a future where AI-designed drugs are routinely tested for their longevity benefits across multiple chronic conditions. For now, the findings offer a tantalizing glimpse—but experts insist that caution remains paramount.

The scientific community will be watching closely for the full peer-reviewed publication of the data, which could appear in a major journal. As one commentary put it, 'If these results hold up in larger trials, they could represent a watershed moment for both AI in medicine and the emerging field of geroscience.' Until then, rentosertib remains an investigational drug with a promising signal, not a proven anti-aging therapy.